Histopathologic response to neoadjuvant chemotherapy: Prognostic value independent of BRCA status or bevacizumab use

Leah Marsh,Teresa Kim,Mingyan Zhang,Sanaz Memarzadeh,Tiffany Lai,Ritu Salani,Beth Karlan,Kari Kubalanza,Jianyua Rao,Gottfried Konecny

GYNECOLOGIC ONCOLOGY（2023）

引用 0|浏览8

暂无评分

摘要

The Chemotherapy Response Score (CRS) has been suggested to be a prognostic marker of relapse, platinum sensitivity, and survival in ovarian cancer (OC). The aim of the present study was to validate the utility of a three-tier CRS and determine if its prognostic value is independent of BRCA status or the use of neoadjuvant bevacizumab.

查看译文

关键词

neoadjuvant chemotherapy,bevacizumab use,brca status

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要